Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01555749 | Investigation of the Pharmacokinetics of NNC172-2021, at Two Different Dose Levels, in Healthy Japanese Subjects | PHASE1 | COMPLETED | 8 | — | — | Mar 12, 2012 | May 8, 2012 | Feb 27, 2017 | 1 | United Kingdom |
| Arm | Type | Description |
|---|---|---|
| NNC172-2021 low dose / Placebo | EXPERIMENTAL | - |
| NNC172-2021 high dose / Placebo | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| NNC172-2021 | DRUG | One injection administered subcutaneously (s.c., under the skin). Injection of maximum 1.2 mL |
| placebo | DRUG | One injection administered subcutaneously (s.c., under the skin) |
Inclusion Criteria: * Healthy male Japanese subjects defined as: Subjects born in Japan, time residing outside of Japan does not exceed 5 years, both parents and all 4 grandparents of Japanese descent * Body weight between 50 and 100 kg, both inclusive * Body mass index (BMI) between 18.0 and 30.0 ...